Trial Profile
A phase III trial of cefilavancin (TD-1792) for complicated skin and soft tissues infections (cSSSI), caused by gram-positive bacteria
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2016
Price :
$35
*
At a glance
- Drugs Cefilavancin (Primary)
- Indications Gram-positive infections; Skin and soft tissue infections
- Focus Therapeutic Use
- 21 Jan 2016 New trial record